APA (7th ed.) Citation

Kauer, J., Freundt, E. P., Schmitt, A., Weinhold, N., Mai, E. K., Müller-Tidow, C., . . . Sauer, S. (2023). Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: A single centre experience from the GMMG-HD6 and -HD7 trials. BMC cancer, 23, . https://doi.org/10.1186/s12885-023-11507-9

Chicago Style (17th ed.) Citation

Kauer, Joseph, et al. "Stem Cell Collection After Lenalidomide, Bortezomib and Dexamethasone Plus Elotuzumab or Isatuximab in Newly Diagnosed Multiple Myeloma Patients: A Single Centre Experience from the GMMG-HD6 and -HD7 Trials." BMC Cancer 23 (2023). https://doi.org/10.1186/s12885-023-11507-9.

MLA (9th ed.) Citation

Kauer, Joseph, et al. "Stem Cell Collection After Lenalidomide, Bortezomib and Dexamethasone Plus Elotuzumab or Isatuximab in Newly Diagnosed Multiple Myeloma Patients: A Single Centre Experience from the GMMG-HD6 and -HD7 Trials." BMC Cancer, vol. 23, 2023, https://doi.org/10.1186/s12885-023-11507-9.